INTERVIEWS

Dr. Randeep Suneja, of the Cardiology Center of Houston​, a quintuple board-certified cardiologist discusses his prescribing experience with Leqvio (inclisiran) injection, key learnings, and experiences working with Alternate Injection Centers (AICs) ​when prescribing Leqvio​, discussions he has had with colleagues​ in the cardiology community about the drug, and decision-making conversations with patients.

Rayne Guest, Founder & CEO of ArrowClean discusses healthcare-acquired infections and her patented device that produces TK60, among the most effective disinfectants in the world and used by U.S. hospital systems. EPA-audited, the hypoallergenic disinfectant is made on-site, produced for a fraction of the cost, and effective against a wide range of harmful pathogens. Microchem Laboratory initially verified TK60 as a one-minute healthcare-grade disinfectant in December 2014. In January 2021, they confirmed that ArrowClean’s TK60 eliminated 99.99% of human coronavirus on nonporous surfaces in just 20 seconds, 30 times faster than most EPA-approved disinfectants.

Returning guest, Brad Chapman, Head of the U.S. Neurology, Epilepsy and Rare Syndrome Portfolio at UCB, a global biopharma company, discusses the launch of partnerships with Le Bonheur Children’s Hospital, the Wisconsin Health Information Organization (WHIO), and Yale University aimed at understanding the economic and clinical impacts of undertreating seizure clusters and explore drivers of better outcomes in addition to examining the impact of seizure clusters on patient and caregiver quality of life – an under-examined area of epilepsy research. Seizure clusters are episodes of increased seizure activity, defined by having two or more seizures occur within a 24-hour period.

Kim Boericke, Chief Delivery Officer at THREAD, a platform for decentralized clinical trials (DCTs) discusses DCTs and some of the barriers that exist in traditional clinical trials. She talks about what THREAD has to offer that makes DCTs more effective, efficient, and easier.

Jenn Tardy, Inclusive Recruiting Expert and Career Coach and Dr. Merle Diamond, President and Medical Director at Diamond Headache Clinic discuss migraine and findings from a recent Harris Poll survey titled “Working Through Migraine.” Jennifer shares tips such as how to make workplaces more migraine-friendly and how to talk with your boss about migraine, and Dr. Diamond shares information about an FDA-approved medication available for the preventive treatment of episodic migraine in adults.

Dr. Charlene Gamaldo, Medical Director of the Johns Hopkins Center for Sleep at Howard County General Hospital and Professor of Neurology, Johns Hopkins University discusses the daytime impact of insomnia and key findings from The Wake Up America Survey conducted by the Alliance for Sleep and Idorsia Pharmaceuticals, U.S. Inc. 

Returning guest, Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda, discusses the approval of the company’s dengue vaccine, QDENGA ® (TAK-003), in Indonesia for those six years to 45 years of age. It is the only dengue vaccine approved in Indonesia that does not require pre-vaccination testing. The approval is based on the positive long-term results from the pivotal Phase 3 TIDES trial through 36 months follow-up. QDENGA is currently undergoing regulatory review in the European Union and other dengue-endemic countries outside the EU through the EU-M4all procedure with some decisions expected in Takeda’s FY22. Takeda also plans to file in the U.S. soon. More on the announcement here.   

Dr. Maria Montero, Associate Director of Clinical Training for Orbis’s Flying Eye Hospital discusses the one-of-a-kind fully accredited ophthalmic teaching hospital and Orbis’s long-standing partnership with Alcon. In this segment, Dr. Montero speaks about the Flying Eye Hospital’s recent visit to Fort Worth, Texas, where Orbis’s clinical staff and Volunteer Faculty (medical experts) along with Alcon bioengineers and trainers shared their knowledge with nearly 50 ophthalmologists, ophthalmology residents, nurses and biomedical engineers from several countries throughout the Caribbean, helping them build skills to fight avoidable blindness in their communities.

Matthew Zierhut, Vice President, Integrated Drug Development ​discusses case studies that exemplify the importance of model-based meta-analysis and biosimulation in early-stage drug development to improve clinical trial success. 

Returning guest, Nelson Ambrogio, Senior Vice President and General Manager Oncology, Bayer Pharmaceuticals US, discusses the FDA approval of NUBEQA ® (darolutamide) in combination with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). He talks about what this approval means for those living with prostate cancer and the current treatment landscape, what’s next for NUBEQA, and the future of Bayer in oncology.